Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095361 · ClinicalTrials.gov registry record · Phase 4
Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 270
- Enrollment target
NCT07095361 is a Phase 4 study that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 270 participants.
The verdict
NCT07095361, a Phase 4 study, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 270 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections around the lungs (called pleural infections). These medications-tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)-are placed through a chest tube into the space between the lung and the chest wall to help clear out the infection. The investigators are trying to learn: * Does using the medicine once a day work just as well as using it twice a day? * Are there any differences in outcomes between patients who get the medicine once a day versus twice a day? * Does more or less fluid remain in the chest (seen on a chest x-ray) depending on how often the medicine is given? Participants will: * Have an infection around their lung and will already be getting normal hospital care, including a chest tube to drain the infected fluid around their lung. * Be asked to give permission to join the study. * Be randomly chosen (like flipping a coin) to get the medications either once a day or twice a day through the chest tube.
Interventions
- DRUG Fibrinolytic once daily
- DRUG Fibrinolytic twice daily
- DRUG DNA degradation once daily
- DRUG DNA degradation twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2025-09-11 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07095361
The ClinicalTrials.gov registry entry for NCT07095361 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fibrinolytic once daily is the first listed.
NCT07095361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07095361 about?
NCT07095361 is a clinical study titled "Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema". The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections around the lungs (called pleural infections). These medications-tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)-are placed throug...
What is the current status of trial NCT07095361?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 270 participants. The study started on 2025-09-11. Estimated completion is 2028-09-30.
What interventions are being tested in trial NCT07095361?
The interventions under investigation include: Fibrinolytic once daily (DRUG), Fibrinolytic twice daily (DRUG), DNA degradation once daily (DRUG), DNA degradation twice daily (DRUG).
Who is sponsoring clinical trial NCT07095361?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.